Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: AMN001
MIFTS: 54

Amenorrhea

Categories: Reproductive diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Amenorrhea

About this section

MalaCards integrated aliases for Amenorrhea:

Name: Amenorrhea 12 74 6 43 15 17 71
Absence of Menstruation 12
Amenia 12

Classifications:

MalaCards categories:
Anatomical: Reproductive diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:13938
ICD9CM 34 626.0
MeSH 43 D000568
NCIt 49 C61443
SNOMED-CT 67 14302001
ICD10 32 N91.2
UMLS 71 C0002453
Sources

Summaries for Amenorrhea

About this section
Disease Ontology : 12 A female reproductive system disease that is characterized by the absence of menstruation.

MalaCards based summary : Amenorrhea, also known as absence of menstruation, is related to hypogonadotropic hypogonadism 23 without anosmia and blepharophimosis, ptosis, and epicanthus inversus, and has symptoms including menometrorrhagia and ovulation bleeding. An important gene associated with Amenorrhea is FSHR (Follicle Stimulating Hormone Receptor), and among its related pathways/superpathways are Peptide ligand-binding receptors and DAG and IP3 signaling. The drugs Cyproterone Acetate and Desogestrel have been mentioned in the context of this disorder. Affiliated tissues include pituitary, bone and ovary, and related phenotypes are endocrine/exocrine gland and homeostasis/metabolism

Wikipedia : 74 Amenorrhea is the absence of a menstrual period in a woman of reproductive age. Physiological states of... more...

Sources

Related Diseases for Amenorrhea

About this section

Diseases related to Amenorrhea via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 616)
# Related Disease Score Top Affiliating Genes
1 hypogonadotropic hypogonadism 23 without anosmia 32.8 LHB GNRH1
2 blepharophimosis, ptosis, and epicanthus inversus 32.7 NR5A1 FOXL2 BMP15
3 galactorrhea 32.1 PRL IGF1
4 pituitary adenoma, prolactin-secreting 31.9 PRL POMC NR5A1 IGF1 GNRH1
5 kallmann syndrome 31.8 SHBG PRL NR5A1 LEP GNRH1 FSHR
6 anorexia nervosa 31.2 SHBG PRL POMC LEP INS IGF1
7 pituitary tumors 31.0 PRL POMC IGF1
8 gonadal dysgenesis 31.0 SHBG NR5A1 GDF9 FSHR FOXL2 BMP15
9 eating disorder 30.9 POMC LEP CRH
10 polycystic ovary syndrome 30.9 SHBG PRL POMC LEP INS IGF1
11 adenoma 30.8 PRL POMC LHCGR IGF1 CRH
12 endometriosis 30.7 WNT4 NR5A1 GNRH1 FSHR
13 leydig cell tumor 30.6 NR5A1 LHCGR GNRH1
14 ovarian cyst 30.6 PRL GNRH1 FOXL2
15 diabetes insipidus 30.5 PRL POMC INS CRH
16 chromophobe adenoma 30.5 PRL POMC
17 granulosa cell tumor of the ovary 30.5 PRL INS FOXL2
18 pseudohermaphroditism 30.4 POMC NR5A1 LHCGR LHB FSHR
19 nonsyndromic disorders of testicular development 30.4 WNT4 NR5A1
20 pituitary adenoma 30.4 PRL POMC IGF1 GNRH1 CRH
21 46,xx sex reversal 1 30.4 NR5A1 FSHR BMP15
22 hermaphroditism 30.4 WNT4 SHBG FOXL2
23 pituitary hormone deficiency, combined, 2 30.3 PRL POMC IGF1
24 46 xx gonadal dysgenesis 30.3 NR5A1 NOBOX LHCGR GDF9 FSHR FOXL2
25 hyperprolactinemia 30.3 SHBG PRL POMC INS IGF1 GNRH1
26 premature menopause 30.3 NOBOX GNRH1 GDF9 FSHR FOXL2 BMP15
27 spinocerebellar degeneration 30.3 PRL CRH
28 infertility 30.2 SHBG PRL NR5A1 LHCGR LHB GNRH1
29 galactosemia i 30.2 GDF9 FOXL2 BMP15
30 androgen insensitivity syndrome 30.2 SHBG NR5A1 INS
31 prolactin producing pituitary tumor 30.1 PRL POMC
32 bone resorption disease 30.1 LEP INS IGF1 ERCC6
33 craniopharyngioma 30.1 PRL NR5A1 INS IGF1 GNRH1
34 adrenal adenoma 30.0 POMC INS CRH
35 pseudohypoparathyroidism 30.0 PRL LEP IGF1
36 hypoadrenocorticism, familial 29.9 POMC NR5A1 CRH
37 hypoglycemia 29.9 PRL POMC INS IGF1 CRH
38 hypokalemia 29.9 POMC INS CRH
39 secondary adrenal insufficiency 29.9 INS IGF1
40 hypogonadism 29.8 SHBG PRL LHCGR LHB LEP INS
41 hypogonadotropic hypogonadism 29.8 SHBG PRL NR5A1 LHCGR LHB LEP
42 sleep apnea 29.8 LEP INS IGF1
43 carney complex variant 29.8 PRL POMC IGF1
44 intracranial hypertension, idiopathic 29.7 POMC LEP IGF1
45 acanthosis nigricans 29.7 SHBG PRL LEP INS IGF1
46 empty sella syndrome 29.7 PRL POMC INS IGF1 GNRH1
47 premature ovarian failure 1 29.7 WNT4 SHBG PRL POMC POF1B NR5A1
48 osteoporosis 29.7 SHBG PRL LEP INS IGF1 GNRH1
49 estrogen excess 29.7 SHBG PRL GNRH1 FSHR FOXL2
50 premenstrual tension 29.7 SHBG POMC GNRH1

Graphical network of the top 20 diseases related to Amenorrhea:



Diseases related to Amenorrhea
Sources

Symptoms & Phenotypes for Amenorrhea

About this section

UMLS symptoms related to Amenorrhea:


menometrorrhagia, ovulation bleeding

MGI Mouse Phenotypes related to Amenorrhea:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.41 BMP15 CRH FOXL2 FSHB FSHR GDF9
2 homeostasis/metabolism MP:0005376 10.34 CRH ERCC6 FOXL2 FSHB FSHR GDF9
3 cellular MP:0005384 10.27 CRH ERCC6 FSHB FSHR IGF1 INS
4 growth/size/body region MP:0005378 10.27 CRH ERCC6 FOXL2 FSHR GNRH1 IGF1
5 immune system MP:0005387 10.14 CRH ERCC6 FSHR GNRH1 IGF1 INS
6 adipose tissue MP:0005375 10.11 CRH ERCC6 FSHR IGF1 INS LEP
7 integument MP:0010771 10.07 CRH ERCC6 FSHR GNRH1 IGF1 INS
8 nervous system MP:0003631 9.93 CRH ERCC6 FSHR GNRH1 IGF1 INS
9 liver/biliary system MP:0005370 9.92 CRH ERCC6 GNRH1 INS LEP LHCGR
10 neoplasm MP:0002006 9.8 ERCC6 FSHR GNRH1 IGF1 LEP POMC
11 renal/urinary system MP:0005367 9.56 CRH GNRH1 IGF1 INS LEP LHCGR
12 reproductive system MP:0005389 9.5 BMP15 FOXL2 FSHB FSHR GDF9 GNRH1
Sources

Drugs & Therapeutics for Amenorrhea

About this section

Drugs for Amenorrhea (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 279)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyproterone Acetate Approved, Investigational Phase 4 427-51-0
2
Desogestrel Approved Phase 4 54024-22-5 40973
3
leucovorin Approved Phase 4 58-05-9 6006 143
4
Sodium citrate Approved, Investigational Phase 4 68-04-2
5
Copper Approved, Investigational Phase 4 7440-50-8 27099
6
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
7
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 11953898
8
Nicotine Approved Phase 4 54-11-5 942 89594
9
Cetrorelix Approved, Investigational Phase 4 120287-85-6 16129715 25074887
10
Curcumin Approved, Experimental, Investigational Phase 4 458-37-7 969516
11
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
12
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
13
Tibolone Approved, Investigational Phase 4 5630-53-5
14
Calcium carbonate Approved, Investigational Phase 4 471-34-1
15
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 10204 6013
16
Sargramostim Approved, Investigational Phase 4 83869-56-1, 123774-72-1
17
Lenograstim Approved, Investigational Phase 4 135968-09-1
18
Metformin Approved Phase 4 657-24-9 14219 4091
19
Mifepristone Approved, Investigational Phase 4 84371-65-3 55245
20
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
21
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
22
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
23
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
24
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
25
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
26
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
27
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
28
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
29
Enclomiphene Investigational Phase 4 15690-57-0
30
Cobalamin Experimental Phase 4 13408-78-1 6857388
31
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
32 Molgramostim Investigational Phase 4 99283-10-0
33
Cyproterone Phase 4 2098-66-0 5284537
34 Mitogens Phase 4
35 Dacuronium Phase 4
36 Tin Fluorides Phase 4
37 Estrogens, Conjugated (USP) Phase 4
38 Vitamin B Complex Phase 4
39 Hematinics Phase 4
40 Folate Phase 4
41 Vitamin B9 Phase 4
42 Citrate Phase 4
43 Clomiphene Phase 4
44 Zuclomiphene Phase 4
45 Copper Supplement Phase 4
46 Fenugreek Phase 4
47 Fenugreek seed meal Phase 4
48 Vitamin B 6 Phase 4
49 Vitamin B 12 Phase 4
50 Vitamin B12 Phase 4

Interventional clinical trials:

(show top 50) (show all 296)
# Name Status NCT ID Phase Drugs
1 Phase IV Study of the Use of Two Preparations of Ethinyl Estradiol and Cyproterone Acetate in Irregular Menstruation of Hyper-androgenic Origin Unknown status NCT01103518 Phase 4 Ethinyl Estradiol + Cyproterone acetate
2 Multicenter Randomized Clinical Trial to Evaluate the Safety and Effectiveness of Cavaterm TM Thermal Balloon Endometrial Ablation in Women With Dysfunctional Uterine Bleeding Compared to Transcervical Resection of the Endometrium (TCRE) Unknown status NCT00549159 Phase 4
3 Interest of Placental Alpha-microglobulin-1 Detection Test to Assess Risk of Premature Delivery in Reunion Island Unknown status NCT02904070 Phase 4
4 A Randomized Controlled Trial to Compare the Menstrual Bleeding Profile Among Copper and 13,5mg Levonorgestrel-releasing IUD Users. Unknown status NCT02957292 Phase 4 Levonorgestrel (13,5 mg) intrauterine device
5 Ulipristal Acetate Versus GnRH Analogue Treatment Before Hysteroscopic Resection of Uterine Leiomyoma Unknown status NCT02361879 Phase 4 ulipristal acetate;Leuprolide acetate
6 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in PCOS Patients. Unknown status NCT01246310 Phase 4
7 The Effect of UPA on Women Ovarian Reserve Unknown status NCT02361892 Phase 4 ulipristal acetate
8 The Effects of Contraceptive Pill and Hormonal Vaginal Ring on Hormonal, Inflammatory and Metabolic Parameters in Women of Reproductive Age With Polycystic Ovary Syndrome (PCOS). Unknown status NCT01588873 Phase 4 oc:E-E-desogestrel/vaginal ring:E-E -ethonogestrel
9 IVF Outcome Following Treatment With Ulipristal Acetate for Myomatous Uterus After at Least One IVF Failure Unknown status NCT02601196 Phase 4 Ulipristal acetate
10 Metformin for Treatment Antipsychotic Induced Amenorrhea in Female Schizophrenic Patients: a Double Blind, Placebo-controlled Study Completed NCT01206153 Phase 4 metformin
11 Evaluation of Safety and Efficacy of PROMETRIUM® Capsules in Induction of Secretory Conversion of Endometrium and Withdrawal Bleeding in Subjects With Secondary Amenorrhea Completed NCT00160199 Phase 4 PROMETRIUM® 300 mg;PROMETRIUM® 400 mg
12 Acceptability and Continuation Rate of Implanon in a Brazilian Public Sector Completed NCT01392157 Phase 4
13 Effect of Timing of Postpartum Depot Medroxyprogesterone Acetate Administration on Breastfeeding Continuation, Contraceptive Continuation, and Postpartum Depression: a Randomized Trial Completed NCT01463202 Phase 4 Depot medroxyprogesterone acetate;Depot medroxyprogesterone acetate
14 Is Endometrial Withdrawal Bleeding Necessary Prior to Ovulation Induction With Clomiphene Citrate? A Randomized Controlled Trial and Feasibility Study Completed NCT03309176 Phase 4 Medroxyprogesterone Acetate 10 MG
15 Effect of Polyvitaminics (Pyridoxine Hydrochloride, Folic Acid and Cyanocobalamin) in the Concentration of Homocysteine and Lipid Profile in Postmenopausal Women: a Randomized Controlled, Double-blind Clinical Trial Completed NCT03221816 Phase 4 Tenavit®;Placebo Oral Tablet
16 Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus-Prevalence,Risk Factors and Treatment Completed NCT00668330 Phase 4 Ibandronate+alfacalcidol+calcium;placebo ibandronate+alfacalcidol+calcium
17 Progesterone Augmentation of Nicotine Replacement Therapy Study Completed NCT02685072 Phase 4 Progesterone (200 mgs BID);Placebo
18 Efficacy and Safety of Furocyst in Patients With Poly Cystic Ovary Syndrome Completed NCT02789488 Phase 4
19 Effect Of Hormone Replacement Therapy On Disease Activity, Menopausal Symptoms And Bone Mineral Density In Peri/Postmenopausal Women With Systemic Lupus Erythematosus.Randomized Clinical Trial Completed NCT00392093 Phase 4 Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d
20 CLASSICAL ANTAGONIST PROTOCOL IN COMPARISON WITH AGONIST STOP PROTOCOL IN Polycystic Ovary Symdrome WOMEN UNDERGOING Intra-cytoplasmic Injection TRIAL: a Randomized Controlled Trial Recruiting NCT04094467 Phase 4 Cetrorelix;Leuprolide Acetate
21 Treatment of Unfavorable Bleeding Patterns in Contraceptive Implant Users: a Randomized Clinical Trial of Curcumin Recruiting NCT04205929 Phase 4 Placebo;Curcumin
22 A Randomized Controlled Trial of Vaginal Estrogen to Treat Asymptomatic Microscopic Hematuria Recruiting NCT03033160 Phase 4 Estradiol Ring
23 Impact of Concurrent Initiation of DMPA Contraception and Tenofovir PrEP on Bone Loss in Young Women Recruiting NCT03464266 Phase 4 FTC/TDF;DMPA
24 A Randomized Controlled Trial of Pre-retrieval Triggering Methods in in Vitro Fertilization Patients Classified as Low, Normal or High Responder Recruiting NCT02715336 Phase 4 Ovulation induction with hCG and Lupron (GnRH agonist)
25 Tenofovir As Prevention Of Hepatitis b Mother-to-child Transmission Active, not recruiting NCT02937779 Phase 4 Tenofovir disoproxil fumarate
26 The Effect of Estrogen in the Prevention of Adhesion Reformation After Hysteroscopic Adhesiolysis Enrolling by invitation NCT03620929 Phase 4 Estradiol Valerate
27 Psychological Impact of Amenorrhea in Women With Endometriosis: Perspective Randomized Study Not yet recruiting NCT02393482 Phase 4 Estroprogestinic therapy (Etinil-estradiol/levonorgestre);Gonadotropin-releasing hormone agonist (Leuprorelin acetate);Add back therapy 1 (tibolone);Add back therapy 2 (calcium carbonate/colecalciferol)
28 Gonadotropin and Steroid Hormone Secretion in Transgender Males Not yet recruiting NCT04321551 Phase 4 Recombinant follicle-stimulating hormone;Estradiol Valerate;Progesterone Injectable
29 Autologous Stem Cell Ovarian Transplantation to Restore Ovarian Function in Premature Ovarian Failure Patients. Pilot Study ASCOT-2 Not yet recruiting NCT03535480 Phase 4 G-CSF
30 Body Composition and Metabolic Manifestations of Insulin Resistance in Adolescents With Polycystic Ovary Syndrome: Ectopic Fat Deposition and Metabolic Markers: Intervention and Follow-up Portion Suspended NCT02500147 Phase 4 Metformin;Placebo
31 The Luveris® In Vitro Fertilization Trial: The Effect of Recombinant Luteinizing Hormone on Follicular Response, Oocyte Quality, and Pregnancy in In-Vitro Fertilization Treatment Cycles in Women Without Endogenous LH Activity. Terminated NCT00889512 Phase 4 Luveris fixed dose;Luveris increasing dose
32 Randomized, Open Label, 8-Week Study of Quetiapine and Risperidone on Quality of Life in Female With Schizophrenia Terminated NCT00498004 Phase 4 Quetiapine, Risperidone
33 Mifepristone Tablets in the Treatment of Symptomatic Uterine Fibroids With Safety and Efficacy in Open, Multicenter Phase IV Clinical Studies Terminated NCT03210324 Phase 4 Mifepristone tablets
34 Hydroxyzine Effects on Meal-Related Anxiety in Underweight Adolescents and Young Adults Diagnosed With an Eating Disorder - A Pilot Study Withdrawn NCT01372670 Phase 4 Hydroxyzine;hydroxyzine HCL
35 Effect of Ulipristal Acetate on Bleeding Patterns and Dysmenorrhea in Women With Adenomyosis Withdrawn NCT03325868 Phase 4 Ulipristal Acetate
36 Use of the GnRH Agonist Leuprolide Acetate (Lupron(Registered Trademark)) to Preserve Ovarian Function in Women Undergoing Chemotherapy Withdrawn NCT00507780 Phase 4 GnRH antagonist
37 Prospective Experimental of Tripterygium Glycoside in the Treatment of Crohn's Disease for Induction Remission Unknown status NCT02044952 Phase 2, Phase 3 Mesalazine, Tripterygium glycosides
38 A Randomized Phase III Trial Comparing Nanoparticle-based Paclitaxel With Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Patients With Early Breast Cancer (GeparSepto) Unknown status NCT01583426 Phase 3 nab-Paclitaxel;Paclitaxel
39 Phase 3 Study Investigating the Effect of Endobarrier Treatment on Fertility in Women With Polycystic Ovary Syndrome Unknown status NCT02255578 Phase 3 clomiphene citrate treatment
40 Usefulness of Spironolactone for the Prevention of Acute Kidney Injury in Critically Ill Patients With Invasive Mechanical Ventilation Unknown status NCT03206658 Phase 3 Spironolactone 25 mg;Placebo oral capsule
41 A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating Three Doses of Subcutaneous Pulsatile GnRH Administered Via OmniPod Pump for Ovulation Induction in Female Subjects With Primary Amenorrhea With Hypogonadotropic Hypogonadism Completed NCT01976728 Phase 3 Gonadorelin acetate subcutaneous (SC) 10 μg/pulse as a fixed dose, administered via. OmniPod pump;Gonadorelin acetate SC 15 μg/pulse as a fixed dose, administered via. OmniPod pump;Gonadorelin acetate SC 20 μg/pulse as a fixed dose, administered via. OmniPod pump;Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump)
42 A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer Completed NCT00087178 Phase 3 cyclophosphamide;adriamycin;epirubicin;fluorouracil
43 Effect of Oral Estradiol and Progesterone Therapy on Vaginal Cytokines in Postmenopausal Women Completed NCT02224313 Phase 3 oral estradiol 1.0 mg;oral progesterone 100 mg
44 Mifepristone Versus Placebo to Treat Adenomyosis: a Double-blind, Multicentre，Randomized Clinical Trial Completed NCT03520439 Phase 2, Phase 3 Mifepristone;Placebo
45 A Double Blind Randomized Controlled Trial to Study the Effectiveness of a Levonorgestrel Releasing Intrauterine Device for the Treatment of Pelvic Pain or Dysmenorrhea in the Patients Undergone Conservative Surgery for Pelvic Endometriosis Completed NCT00455845 Phase 3
46 Parallel-Group Comparative Study of SJ-0021 and Purified Pituitary Gonadotropin in Subjects With Amenorrhea I or Anovulatory Cycles - Phase III Single-Blind Study Completed NCT01185782 Phase 3 Gonalef® (Follitropin alfa);Purified pituitary gonadotropin (Fertinorm-P®)
47 A Randomized, Placebo Controlled Trial Of Zoledronic Acid For The Prevention Of Bone Loss In Premenopausal Women With Early Stage Breast Cancer Completed NCT00049452 Phase 3 zoledronic acid
48 Feasibility Study of the Measurement of the Placental Perfusion During the First Trimester of Pregnancy by 3D Doppler Echo-angiography With a Contrast Agent Completed NCT02884297 Phase 3 Contrast agent: SonoVue®.
49 Antenatal Multiple Micronutrient Supplementation to Improve Infant Survival and Health in Bangladesh Completed NCT00860470 Phase 3
50 Effects of Metformin on Fertility and Pregnancy in Women With Polycystic Ovary Syndrome: a Randomized, Prospective, Placebo-controlled Multicenter Study Completed NCT00994812 Phase 3 metformin

Search NIH Clinical Center for Amenorrhea

Inferred drug relations via UMLS 71 / NDF-RT 50 :


17-alpha-Hydroxyprogesterone
2-Bromoergocryptine Mesylate
Bromocriptine
Gonadorelin
Gonadorelin Acetate
Gonadorelin Hydrochloride
hydroxyprogesterone caproate (USP)
Medroxyprogesterone
medroxyprogesterone acetate
norelgestromin
Norethynodrel
norgestimate
Progesterone
PROGESTERONE PWDR

Cochrane evidence based reviews: amenorrhea

Sources

Genetic Tests for Amenorrhea

About this section
Sources

Anatomical Context for Amenorrhea

About this section

MalaCards organs/tissues related to Amenorrhea:

40
Pituitary, Bone, Ovary, Breast, Testes, Uterus, Liver
Sources

Publications for Amenorrhea

About this section

Articles related to Amenorrhea:

(show top 50) (show all 9903)
# Title Authors PMID Year
1
The impact of menstruation persistence or recovery after chemotherapy on survival in young patients with hormone receptor negative breast cancer. 61
32497987 2020
2
Thinness and fecundability: Time to pregnancy after adolescent marriage in rural Bangladesh. 61
32207581 2020
3
NSAS-BC02 substudy of chemotherapy-induced amenorrhea (CIA) in premenopausal patients who received either taxane alone or doxorubicin(A) cyclophosphamide(C) followed by taxane as postoperative chemotherapy. 61
32462261 2020
4
Clinical and genetic analysis of an isolated follicle-stimulating hormone deficiency female patient. 61
32367462 2020
5
Do nothing but observe microprolactinomas: when and how to replace sex hormones? 61
32274622 2020
6
Recurring Primary Xanthomatous Hypophysitis Behaving Like Pituitary Adenoma: Additional Case and Literature Review. 61
32081821 2020
7
Mayer-Rokitansky-Küster-Hauser syndrome with a solitary duplex kidney and anal stenosis: a rare case report. 61
32561448 2020
8
A Novel Phenotype Combining Primary Ovarian Insufficiency Growth Retardation and Pilomatricomas With MCM8 Mutation. 61
32242235 2020
9
Gonadotropin-releasing hormone antagonist (linzagolix): a new therapy for uterine adenomyosis. 61
32507315 2020
10
A case series of patients with gonadal dysgenesis-associated mixed malignant ovarian germ cell tumor. 61
32516003 2020
11
A retrospective multicenter study of bone mineral density in adolescents and adults with Turner syndrome in Japan. 61
32554947 2020
12
POI after chemotherapy and bone marrow transplant may mimic disorders of sexual differentiation - a case report of a patient with primary amenorrhea and 46, XY karyotype. 61
31858843 2020
13
Transient hyperprolactinemia secondary to benzodiazepines: a case report. 61
32576545 2020
14
Characteristics and prognosis of borderline ovarian tumors in pre and postmenopausal patients. 61
32556512 2020
15
Drospirenone 4 mg-only pill (DOP) in 24+4 regimen: a new option for oral contraception. 61
32538188 2020
16
Relative energy deficiency in sports (RED-S): elucidation of endocrine changes affecting the health of males and females. 61
32557402 2020
17
Indexes of aortic wave reflection are not augmented in estrogen-deficient physically active premenopausal women. 61
32119140 2020
18
Associations of Perfluoroalkyl Substances with Incident Natural Menopause: the Study of Women's Health Across the Nation. 61
32491182 2020
19
The study on the safety and efficacy of amnion graft for preventing the recurrence of moderate to severe intrauterine adhesions. 61
32215296 2020
20
Bone Infections, Sinusitis, Antihypertensive Therapy and COVID-19, Toilet Training, Amenorrhea. 61
32538595 2020
21
Polycystic ovary Syndrome in Adolescents: Pitfalls in Diagnosis and Management. 61
32504286 2020
22
Effect of a pulse-based diet and aerobic exercise on bone measures and body composition in women with polycystic ovary syndrome: A randomized controlled trial. 61
32071953 2020
23
Population-based Data at Ages 31 and 46 Show Decreased HRQoL and Life Satisfaction in Women with PCOS Symptoms. 61
31970392 2020
24
Study of frequency and types of chromosomal abnormalities in phenotypically female patients with amenorrhea in Eastern Indian population. 61
32515109 2020
25
Perioperative nursing care of a patient with urogenital sinus malformation who underwent vaginal calculus removal and correction: a case report. 61
32552122 2020
26
Secondary Prevention of Intrauterine Adhesions Following Hysteroscopic Surgery in Women With Asherman Syndrome: Is Something Better Than Nothing? 61
31815774 2020
27
Female Athlete Triad Coalition Cumulative Risk Assessment Tool: Proposed alternative scoring strategies. 61
32502379 2020
28
Laparoscopic Excision of the Retroperitoneal Mullerian Cyst in a Different Location. 61
31874314 2020
29
Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone-antagonist: a randomized clinical trial. 61
32505383 2020
30
Factors of mineral homeostasis impairment and bone mineral density loss in women with central hypogonadism. 61
32519580 2020
31
A Dozen Testosterone Samples From One Patient, on One Day? 61
32539123 2020
32
Fifteen-minute consultation: a structured approach to the child with primary amenorrhea. 61
32561551 2020
33
Hemorrhagic Presentation of Rathke Cleft Cysts: A Surgical Case Series. 61
31504863 2020
34
LEYDIG CELL HYPOPLASIA: A UNIQUE PARADOX IN THE DIAGNOSIS OF 46,XY DISORDERS OF SEX DEVELOPMENT. 61
32524024 2020
35
Low Bone Mineral Density in Elite Female Athletes With a History of Secondary Amenorrhea in Their Teens. 61
32341292 2020
36
Genetic contributions to the etiology of anorexia nervosa: New perspectives in molecular diagnosis and treatment. 61
32368866 2020
37
First custom next-generation sequencing infertility panel in Latin America: design and first results. 61
32155011 2020
38
Dysgerminoma in a Prepubertal Girl with Complete 46XY Gonadal Dysgenesis: Case Report and Review of the Literature. 61
32380037 2020
39
Primary Ovarian Insufficiency Nationwide Incidence Rate and Etiology Among Israeli Adolescents. 61
31987720 2020
40
Familial primary ovarian insufficiency associated with a SYCE1 point mutation: defective meiosis elucidated in humanized mice. 61
32402064 2020
41
Fundamental role of BMP15 in human ovarian folliculogenesis revealed by null and missense mutations associated with primary ovarian insufficiency. 61
31957178 2020
42
Amenorrhea secondary to vismodegib: An adverse event to consider especially in female patients with Gorlin-Goltz syndrome. 61
32383228 2020
43
Predictive factors of preterm delivery in French Guiana for singleton pregnancies: definition and validation of a predictive score. 61
30394157 2020
44
Gynecologic Management of Adolescents and Young Women With Seizure Disorders: ACOG Committee Opinion Summary, Number 806. 61
32332410 2020
45
Gynecologic Management of Adolescents and Young Women With Seizure Disorders: ACOG Committee Opinion, Number 806. 61
32332416 2020
46
Neovaginoplasty Using Nile Tilapia Fish Skin as a New Biologic Graft in Patients with Mayer-Rokitansky-Küster-Hauser Syndrome. 61
31546063 2020
47
Experiences of fathers having faced with termination of pregnancy for foetal abnormality. 61
32428779 2020
48
Long-Term Follow-Up and Treatment of a Female With Complete Estrogen Insensitivity. 61
32152632 2020
49
Successful live birth in a woman with resistant ovary syndrome treated with letrozole and HMG: A case report. 61
32443342 2020
50
Perivascular Stem Cell-Derived Cyclophilin A Improves Uterine Environment with Asherman's Syndrome via HIF1α-Dependent Angiogenesis. 61
32534604 2020
Sources

Variations for Amenorrhea

About this section

ClinVar genetic disease variations for Amenorrhea:

6 ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 FSHR NM_000145.3(FSHR):c.2T>C (p.Met1Thr)SNV Pathogenic 523337 rs955385021 2:49381555-49381555 2:49154416-49154416
2 FSHR NM_000145.3(FSHR):c.153-11T>ASNV Uncertain significance 523336 rs1553340669 2:49295440-49295440 2:49068301-49068301
Sources

Expression for Amenorrhea

About this section
Search GEO for disease gene expression data for Amenorrhea.
Sources

Pathways for Amenorrhea

About this section

Pathways related to Amenorrhea according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Peptide ligand-binding receptors 65
Show member pathways
 13.39 WNT4 PRL POMC LHCGR LHB LEP
2
DAG and IP3 signaling 65
Show member pathways
 12.91 POMC NR5A1 LHCGR LHB FSHR FSHB
3
Aldosterone synthesis and secretion 36
Show member pathways
 12.72 WNT4 POMC NR5A1 INS CRH
4
Prolactin Signaling Pathway 36 1
Show member pathways
 12.33 PRL LHCGR LHB LEP INS
5
cAMP signaling pathway 36
12.17 POMC LHCGR LHB FSHR FSHB
6
Peptide hormone metabolism 65
Show member pathways
 12.06 POMC LHB LEP INS IGF1 FSHB
7
G alpha (s) signalling events 65
11.8 POMC LHCGR LHB FSHR FSHB CRH
8
Mesenchymal Stem Cells and Lineage-specific Markers 64
11.74 WNT4 LEP INS IGF1
9
Signaling events mediated by PTP1B 1
11.37 PRL LEP INS
10
Ovarian Infertility Genes 1
11.17 NR5A1 LHCGR GDF9 FSHR
11
Ovarian steroidogenesis 36
10.87 LHCGR LHB INS IGF1 FSHR FSHB
12
Antipsychotics Pathway (Metabolic Side Effects), Pharmacodynamics 60
10.86 PRL POMC LEP INS
13
G-protein signaling_Rap2B regulation pathway 22
10.84 LHB IGF1 GNRH1 GDF9 BMP15
14
Hormone ligand-binding receptors 65
10.47 LHCGR LHB GNRH1 FSHR FSHB
15
Glucocorticoid Pathway (HPA Axis), Pharmacodynamics 60
10.36 POMC CRH
Sources

GO Terms for Amenorrhea

About this section

Cellular components related to Amenorrhea according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.77 WNT4 SHBG PRL POMC LHB LEP
2 extracellular space GO:0005615 9.4 WNT4 PRL POMC LHB LEP INS
3 Golgi lumen GO:0005796 9.33 WNT4 LHB INS

Biological processes related to Amenorrhea according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.14 PRL POMC LHCGR LHB LEP INS
2 G protein-coupled receptor signaling pathway GO:0007186 10.11 POMC LHCGR LHB INS GNRH1 FSHR
3 positive regulation of gene expression GO:0010628 10 NR5A1 INS IGF1 FSHB ERCC6 CRH
4 positive regulation of cell proliferation GO:0008284 9.98 PRL LEP INS IGF1 GDF9 FSHB
5 cell-cell signaling GO:0007267 9.92 POMC LHB INS GNRH1
6 cellular protein metabolic process GO:0044267 9.92 PRL INS IGF1 BMP15
7 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.78 LEP INS IGF1 FSHR
8 male gonad development GO:0008584 9.77 WNT4 NR5A1 LHCGR LHB FSHR
9 female pregnancy GO:0007565 9.72 PRL LEP GNRH1 FSHB CRH
10 adrenal gland development GO:0030325 9.67 WNT4 NR5A1 CRH
11 regulation of osteoclast differentiation GO:0045670 9.63 FSHR FSHB
12 male sex determination GO:0030238 9.63 NR5A1 GNRH1
13 hormone metabolic process GO:0042445 9.63 WNT4 NR5A1 LEP
14 regulation of steroid biosynthetic process GO:0050810 9.61 NR5A1 LEP
15 positive regulation of follicle-stimulating hormone secretion GO:0046881 9.61 LEP FOXL2
16 bone mineralization involved in bone maturation GO:0035630 9.6 LEP IGF1
17 Sertoli cell proliferation GO:0060011 9.59 FSHR FSHB
18 ovulation cycle process GO:0022602 9.58 LHCGR FSHR
19 negative regulation of glucagon secretion GO:0070093 9.58 LEP CRH
20 follicle-stimulating hormone signaling pathway GO:0042699 9.57 FSHR FSHB
21 positive regulation of luteinizing hormone secretion GO:0033686 9.56 LEP FOXL2
22 female gonad development GO:0008585 9.56 WNT4 NR5A1 FSHR FOXL2
23 progesterone biosynthetic process GO:0006701 9.55 LHB FSHB
24 oocyte growth GO:0001555 9.54 GDF9 FOXL2
25 female gamete generation GO:0007292 9.46 GDF9 FSHR FSHB BMP15
26 hormone-mediated signaling pathway GO:0009755 9.35 NR5A1 LHCGR LHB FSHR FSHB
27 ovarian follicle development GO:0001541 9.1 NOBOX LHCGR FSHR FSHB FOXL2 BMP15

Molecular functions related to Amenorrhea according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.55 WNT4 POMC LHB LEP CRH
2 insulin-like growth factor receptor binding GO:0005159 9.32 INS IGF1
3 hormone activity GO:0005179 9.28 PRL POMC LHB LEP INS IGF1
4 protein-hormone receptor activity GO:0016500 9.26 LHCGR FSHR
5 type I activin receptor binding GO:0070698 8.96 GDF9 BMP15
Sources

Sources for Amenorrhea

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....